Conversely, large cardiovascular-outcome trials such as EMPA-REG OUTCOME demonstrated that sodium–glucose cotransporter-2 (SGLT2) inhibitors confer significant reductions in cardiovascular death, heart-failure hospitalisation and renal decline, benefits that transcend glucose lowering and have prompted many societies to promote these agents early in the treatment algorithm [3,4]. Here, SLC5A2 is linked to heart failure.